Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.
Also called NCT06528262
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 390 participants
- Sponsor
- Registry
-
NCT06528262
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06528262. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-03 (actual); primary completion 2027-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
- Acronym
- ENAVO-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Enavogliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct06528262- Content hash
0211b73375eb3a5c1baa821db36fc7f9c7825656cfeed8537a535a5b6f2ece65